Cover Image
市場調查報告書

色素性視網膜炎(視網膜炎):開發平台分析

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200486
出版日期 內容資訊 英文 146 Pages
訂單完成後即時交付
價格
Back to Top
色素性視網膜炎(視網膜炎):開發平台分析 Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 146 Pages
簡介

色素性視網膜炎(RP),是作用於視網膜的一連串遺傳性眼科疾病的通稱。RP會對光受體細胞(視網膜內部偵測光的細胞)造成破壞,由於光受體細胞具有捕捉、處理光線使眼睛有看見東西的效果,光受體細胞遭到破壞、壞死將導致視力逐漸喪失。各種RP的共通特徵更是視桿細胞(偵測微光的視網膜細胞)和錐體細胞(偵測光、色彩的視網膜細胞)逐漸喪失,不過最初階段大部分是喪失視桿細胞。這種形態的RP(也叫桿錐細胞退化),會先從夜盲症開始。所謂夜盲症,是類似於我們從明亮的戶外進入黑暗的電影院中所感到的感覺那樣的症狀。

本報告提供全球各國的色素性視網膜炎(視網膜炎)所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 分析範圍

色素性視網膜炎(視網膜炎)概要

治療藥的開發

  • 色素性視網膜炎(視網膜炎)開發中產品:概要
  • 色素性視網膜炎(視網膜炎)開發中產品:比較分析

各企業正在開發的色素性視網膜炎(視網膜炎)治療藥

大學/研究機關研究中的色素性視網膜炎(視網膜炎)治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

色素性視網膜炎(視網膜炎)治療藥:開發中的產品一覽(各企業)

色素性視網膜炎(視網膜炎)治療藥:研究中的產品一覽(各大學/研究機關)

色素性視網膜炎(視網膜炎)開發治療藥的企業

  • Acucela Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Amgen Inc.
  • Applied Genetic Technologies Corporation
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Caladrius Biosciences, Inc.
  • Dompe Farmaceutici S.p.A.
  • Genable Technologies Limited
  • Genethon
  • GenSight Biologics S.A.
  • Grupo Ferrer Internacional, S.A.
  • ID Pharma Co., Ltd.
  • InFlectis BioScience
  • International Stem Cell Corporation
  • Ionis Pharmaceuticals, Inc.
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Nanovector s.r.l.
  • Orphagen Pharmaceuticals, Inc.
  • QLT Inc.
  • RegenxBio Inc.
  • ReNeuron Group Plc
  • SanBio, Inc.
  • Sanofi
  • Shire Plc
  • Spark Therapeutics, Inc.
  • Staidson (Beijing) Biopharmaceuticals Co.,td.
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd

肝臟病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

肝臟病治療藥:最新的開發平台趨勢

肝臟病治療藥:開發暫停的產品

肝臟病治療藥:開發中止的產品

肝臟病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9485IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 22 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 1 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinitis Pigmentosa (Retinitis) - Overview
    • Retinitis Pigmentosa (Retinitis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
    • Acucela Inc
    • Allergan Plc
    • Amarantus Bioscience Holdings Inc
    • Amgen Inc
    • Applied Genetic Technologies Corp
    • Asklepios BioPharmaceutical Inc
    • Astellas Pharma Inc
    • Caladrius Biosciences Inc
    • Dompe Farmaceutici SpA
    • GenSight Biologics SA
    • Grupo Ferrer Internacional SA
    • ID Pharma Co Ltd
    • InFlectis BioScience
    • Ionis Pharmaceuticals Inc
    • M's Science Corp
    • Mimetogen Pharmaceuticals Inc
    • Nanovector srl
    • Novartis AG
    • Novelion Therapeutics Inc
    • ProQR Therapeutics NV
    • ReNeuron Group Plc
    • SanBio Inc
    • Sanofi
    • Shire Plc
    • Spark Therapeutics Inc
    • Sun Pharma Advanced Research Company Ltd
  • Retinitis Pigmentosa (Retinitis) - Drug Profiles
    • A-004 - Drug Profile
    • AMRS-001 - Drug Profile
    • Antibodies to Antagonize IL-6 for Retinitis - Drug Profile
    • AP-1 - Drug Profile
    • BNP-RP - Drug Profile
    • cenegermin - Drug Profile
    • CPK-850 - Drug Profile
    • cutamesine - Drug Profile
    • FAB-111 - Drug Profile
    • Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile
    • Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile
    • Gene Therapy for Ocular Diseases - Drug Profile
    • Gene Therapy for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile
    • Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile
    • Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile
    • GS-030 - Drug Profile
    • GT-038 - Drug Profile
    • HORAPDE-6B - Drug Profile
    • HORARLBP-1 - Drug Profile
    • IFB-088 - Drug Profile
    • IONISRHO-2.5Rx - Drug Profile
    • KIRA-6 - Drug Profile
    • KUS-187 - Drug Profile
    • LPDF-003 - Drug Profile
    • myriocin - Drug Profile
    • N-acetyl cysteine amide - Drug Profile
    • NT-501 - Drug Profile
    • OCU-100 - Drug Profile
    • QRX-411 - Drug Profile
    • ReN-003 - Drug Profile
    • RST-001 - Drug Profile
    • SAR-421869 - Drug Profile
    • SB-623 - Drug Profile
    • SHP-630 - Drug Profile
    • Small Molecule for Retinitis Pigmentosa - Drug Profile
    • Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
    • Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile
    • Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile
    • STC-1 - Drug Profile
    • Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile
    • Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
    • Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile
    • Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile
    • Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile
    • voretigene neparvovec - Drug Profile
    • zuretinol acetate - Drug Profile
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products
  • Retinitis Pigmentosa (Retinitis) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top